Navigation Links
DNA2.0 Introduces Simple, IP-Free©, Scarless Cloning
Date:6/5/2013

Menlo Park, Calif. (PRWEB) June 05, 2013

DNA2.0, the leading bioengineering solutions provider, today introduced the Electra Vector System, a universal cloning system for simple, scarless cloning. The Electra system is completely free from licensing restrictions and provides researchers from a large variety of disciplines a much-needed advantage to current cloning methodology.

Systems that facilitate easy movement of DNA elements from one context to another allow many genetic constructs to be rapidly built and tested. DNA2.0 has developed a simple, PCR-free, one-tube universal cloning process that can be performed in a five-minute bench-top reaction with the fidelity of a restriction-based cloning system.

“For a cloning system to be truly universal, researchers should be able to easily utilize their constructs in multiple vector systems without licensing headaches. DNA2.0 developed the Electra Vector System because our customers deserve an efficient, rapid and reliable approach to cloning that is IP-Free,” said Jeremy Minshull, CEO and cofounder of DNA2.0. “Unlike alternative systems, with Electra there are no intellectual property entanglements, no unwanted mutations from polymerases and no sequence scars to affect expression and function.”

The Electra Vector System has 3 major components: pMOTHER vectors which contain the gene of interest, pDAUGHTER vectors (currently >100 vectors) for expression screening and the Electra Reagent Kit for one-step cloning. Electra DAUGHTER vectors are available for purchase independently from DNA2.0. Electra MOTHER vectors are available for individual purchase from the DNA2.0 catalog or by utilizing the DNA2.0 gene synthesis service.

The Electra system takes advantage of the type IIS restriction enzyme SapI developed by New England Biolabs. The key properties of SapI include a sufficiently rare 7bp non-palindromic recognition sequence and a 3bp 5’overhang after digestion that can be designed for any sequence (e.g., the universal ATG start codon and a universal STOP codon). The Electra system can also be used to combine multiple sequence elements simultaneously, facilitating the easy construction of combinatorial libraries, either in a single tube, or in individually enumerated combinations. Any vector can be easily ‘Electrafied’, i.e., converted to function as an Electra DAUGHTER vector, and DNA2.0’s Ph.D.-level customer support scientists can assist customers in determining the best cloning strategy for their research.

About DNA2.0

DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10802605.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. DNA2.0 Patents New DNA Cloning Method
2. DNA2.0 Patents Key Method for Synthesizing Bioplastic Polymer
3. Rigaku Introduces the Fastest 1D Detector for XRD Analysis
4. Allegheny General Hospital Cardiovascular Team Introduces New MRI Capability for Patients with Pacemakers, Implantable Defibrillators
5. Watlow Introduces Its New Industrial Heater Catalog
6. RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software
7. INTIO Introduces TipTRAC™, its Newest Feature for its ClearStart SVM™ Intraoperative Imaging System
8. SeraCare Introduces New Hepatitis C ACCUVERT Seroconversion Panels and Anti-Herpes ACCUSET Performance Panel
9. NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow
10. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
11. Montclair Breast Center introduces 3D Mammography.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... 2016 ReportsnReports.com adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):